Development of Novel VEGFR2 Inhibitors Originating from Natural Product Analogues with Antiangiogenic Impact
作者:Sung Min Cho、Yonghyo Kim、Yooju Jung、Minjeong Ko、Gyorgy Marko-Varga、Ho Jeong Kwon
DOI:10.1021/acs.jmedchem.1c01168
日期:2021.11.11
kinase activity of VEGFR2. Among these Voa structure analogues, Voa analogue 19 (V19) exhibited increased antiangiogenic potency against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects. Moreover, treatment with V19 resulted in significant tumor cell death in a mouse xenograft model. In conclusion, this new VEGFR2 modulator, inspired from the rigid scaffold of a natural compound, Voa, is
一种新型的天然小分子 voacangine (Voa) 已被发现是一种有效的抗血管生成化合物。值得注意的是,Voa 直接结合血管内皮生长因子受体 2 (VEGFR2) 的激酶结构域,从而抑制下游信号传导。在此,我们开发了基于 Voa 独特化学结构的合成小分子,可直接特异性地靶向和调节 VEGFR2 的激酶活性。在这些 Voa 结构类似物中,Voa 类似物 19 (V19) 对 VEGF 诱导的 VEGFR2 磷酸化表现出增强的抗血管生成能力,而没有细胞毒性作用。此外,在小鼠异种移植模型中,V19 治疗导致显着的肿瘤细胞死亡。总之,这种新的 VEGFR2 调节剂受天然化合物 Voa 的刚性支架的启发,